

## Appendix 2 (as supplied by the authors): Meta-regression results for all-cause mortality

Explanatory variable(s)			Summary of effect		
	Median (range)	n (%)	No. of studies/ No. of participants	RRR (95% CI)	P-value
<b>Univariable meta-regression</b>					
Duration of study (y)	3 (0.9,5.3)	-	19/78321	1.02 (0.95,1.09) per 1 y	0.66
Year of study	2003 (1991,2010)	-	19/78321	0.99 (0.97,1.02) per 1 y	0.54
Dose (mg/day)	40 (10,80)	-	19/78321	1.07 (0.99,1.15) per 10 mg/day	0.10
Baseline cholesterol (mmol/L)					
Total	5.95 (4.80,7.27)	-	19/78321	1.00 (0.93,1.08) per -0.5 mmol/L	0.90
LDL	4.03 (2.79,5.17)	-	19/78321	1.00 (0.92,1.08) per -0.5 mmol/L	0.91
HDL	1.27 (0.95,1.64)	-	19/78321	0.79 (0.54,1.16) per 0.5 mmol/L	0.21
Triglycerides	1.70 (1.33,3.60)	-	19/78321	0.99 (0.79,1.24) per -0.5 mmol/L	0.91
% $\Delta$ in LDL (statin arm)*	-28 (-50,-19)	-	18/78198	0.97 (0.89,1.07) per -10%	0.52
Absolute $\Delta$ in LDL (statin arm)	-1.22 (-1.96,-0.75)	-	18/78198	0.94 (0.77,1.16) per -0.5 mmol/L	0.56
Timepoint of LDL measure (y)	0.7 (0.08, 3)	-	16/71095	1.05 (0.99, 1.11) per 0.5 y	0.12
High potency (rosuva or atorva) compared with low potency statins	-	6 (32)	19/78321	0.90 (0.77, 1.07)	0.22
Baseline cardiovascular risk (control arm)**	2.4 (0, 12)	-	13/51335	1.02 (0.99, 1.05) per 1%	0.21
Mean age (y)	58 (51,76)	-	19/78321	1.06 (0.96,1.16) per 5 y	0.22
Percent male	62 (25,100)	-	19/78321	0.98 (0.94,1.02) per 10%	0.28
Percent diabetes	4 (0,35)	-	15/68361	1.05 (1.00,1.11) per 10%	0.07
Percent hypertension	41 (16,100)	-	12/57937	1.02 (0.98,1.06) per 10%	0.28
<b>Multivariable meta-regression</b>					
High potency, and % $\Delta$ in LDL (statin arm)	-28 (-50,-19)	6 (32)	18/78198	0.87 (0.53,1.43) 1.04 (0.82,1.31) per -10%	0.57 0.74
High potency, and absolute $\Delta$ in LDL (statin arm)	-1.22 (-1.96,-0.75)	6 (32)	18/78198	0.91 (0.67,1.24) 1.04 (0.75,1.43) per -0.5 mmol/L	0.54 0.82
<b>Univariable meta-regression (Quality items)</b>					
Unclear allocation concealment (not adequate)	-	13 (68)	19/78321	0.93 (0.79,1.10)	0.38
Not double-blind	-	4 (21)	19/78321	1.10 (0.94,1.28)	0.22
Inadequate description of withdrawals	-	4 (21)	19/78321	0.85 (0.70,1.02)	0.08
Not intention-to-treat	-	2 (11)	19/78321	0.92 (0.66,1.29)	0.62
Private funding only	-	10 (53)	19/78321	0.90 (0.77,1.04)	0.15

$\Delta$  = change; LDL = low-density lipoprotein; HDL = high-density lipoprotein; High intensity = rosuvastatin or atorvastatin; mmol/L = millimoles per litre; mg = milligrams; Rosuva = rosuvastatin; Atorva = atorvastatin; RRR = relative risk ratio

\*first available timepoint at which LDL reduction from baseline is assessed

\*\*defined as rate of cardiovascular death or non-fatal myocardial infarction